Screening tool to collect broader demographic and clinical data. Enhance understanding of site specific and trial specific accrual barriers.

The primary objective of this repository is to make blood samples available for research studies related to histocompatibility and HC transplantation or other cellular therapy.

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.

The purpose of this study is to understand how your gut plays a role in how well CAR T cell therapy works. Your gut is home to bacteria, which we call the gut microbiome. The gut microbiome can send signals to your immune cells, which may impact how well and how long CAR T cell therapy will last. We can find out what type of bacteria are in your gut microbiome by studying your stool. We can understand more about the signals sent to the immune system by studying your blood. We will ask for stool and blood at the same time points throughout your treatment. We will study the identities and function of the bacteria and immune cells to understand more about how these signals work during CAR T cell treatment.

To create digital tools to support young adult cancer survivors completing active treatment and transitioning into survivorship care.

This study will evaluate the use of MMUD PBSC in adults and explore the safety and efficacy of MMUD BM in pediatric recipients with hematological malignancies who may lack other donor options.

To compare the prevalence, severity, and timing of chronic health conditions (CHC) in a cohort of patients with DS-AL (Down Syndrome Acute Leukemia) with age-comparable DS individuals that have no cancer history. Our secondary objectives will compare NP (Neuro-Psychological) and health-related quality of life outcomes in survivors of DS-AL compared with age-comparable DS individuals with no cancer history, and will identify risk determinants of CHC and NP late effects among survivors of DS-AL.

The primary endpoints are to determine the recommended phase 2 dose (RP2D) of SNDX-5613 administered in combination with chemotherapy in patients with relapsed or refractory KMT2A-rearranged (KMT2A-R) acute lymphoblastic leukemia (ALL), and to estimate the minimal residual disease (MRD) negative remission rate of patients with R/R infant KMT2A-R ALL treated with SNDX-5613 in combination with chemotherapy. Secondary endpoints include characterizing the pharmacokinetics (PK) of SNDX-5613 administered with chemotherapy in patients with R/R infant KMT2A-R ALL, estimating the 18-month event-free survival (EFS) of patients with R/R infant KMT2A-R ALL treated with SNDX5613 in combination with chemotherapy, estimating 18-month overall survival (OS) of patients with R/R infant KMT2A-R ALL treated with SNDX5613 in combination with hemotherapy, and characterizing the tolerability of SNDX-5613 given as monotherapy in patients with R/R infant KMT2A-R ALL. The exploratory endpoint is to assess the biologic activity of SNDX-5613 administered with chemotherapy in patients with R/RKMT2A-R ALL.

The purpose of this study is to test the safety of the two study drugs, venetoclax and selinexor, and to find the highest dose of venetoclax and selinexor that can be given safely when it is combined with chemotherapy drugs (cytarabine or cytarabine and fludarabine). This study tests different doses of venetoclax and selinexor to see which dose is safer in children with leukemia.

Cancer caregivers experience high levels of stress related to the caregiving role, particularly for rural caregivers. The purpose of this study is to assess the acceptability and preliminary effect of enCompass Carolina, a social support program for caregivers of rural-dwelling patients with cancer.